Evidence map›Paper›PMID 40959486›Full record

ArticleNanotheranostics2025

Combined physical and biological contributions to radiotherapy enhancement by Lu-based nanoscintillators in pancreatic cancer models.

Sarah Stelse-Masson, Xenie Lytvynenko, Kristel Bedregal-Portugal, Clémentine Aubrun, Matéo Lavaud, Malika Kadri, Thibault Jacquet, Christine Moriscot, Benoit Gallet, Benoit Chovelon and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanotheranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sarah Stelse-MassonGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.
Xenie LytvynenkoFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague 1, 115 19, Czech Republic.
Kristel Bedregal-PortugalGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.
Clémentine AubrunGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.
Matéo LavaudGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.
Malika KadriGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.
Thibault JacquetGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.
Christine MoriscotGrenoble Alpes University, EMBL, Integrated Structural Biology Grenoble (ISBG), UAR3518 CNRS CEA, 38000 Grenoble, France.
Benoit GalletGrenoble Alpes University, Institute of Structural Biology, CNRS CEA, 38000 Grenoble, France.
Benoit ChovelonGrenoble Alpes University, Département de Pharmacochimie Moléculaire, CNRS UMR 5063, 38000 Grenoble, France.
Jean-Luc CollGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.
Jean-Luc RavanatGrenoble Alpes University, CEA, CNRS, Grenoble INP, SyMMES UMR 5819, 38000 Grenoble, France.
Eva MihókováFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague 1, 115 19, Czech Republic.
Václav ČubaFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague 1, 115 19, Czech Republic.
Hélène ElleaumeGrenoble Alpes University, INSERM UA7, Synchrotron Radiation for Biomedicine, 38000 Grenoble, France.
Anne-Laure BulinGrenoble Alpes University, INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, Cancer Targets and Experimental Therapeutics team, 38000 Grenoble, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LutetiumNanoparticlesPancreatic NeoplasmsRadiation-Sensitizing AgentsCell Line, TumorHumansMonte Carlo MethodSilicon DioxideLutetiumRadiation-Sensitizing AgentsSilicon Dioxidenanoscintillatorspancreatic cancerradiation dose-enhancementradiosensitizationradiotherapy

Identifiers

PMID40959486
PMCPMC12435256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.